Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers
Authors
Keywords
Pancreatic cancer, Mutation databases, Next-generation sequencing, Cancer treatment, Frameshift mutation, Cloning, Protein expression, Sequence databases
Journal
PLoS One
Volume 12, Issue 9, Pages e0185687
Publisher
Public Library of Science (PLoS)
Online
2017-09-29
DOI
10.1371/journal.pone.0185687
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- KRAS, BRAF, and PIK3CA mutations, and patient prognosis in 126 pancreatic cancers: pyrosequencing technology and literature review
- (2016) Lei Zhou et al. MEDICAL ONCOLOGY
- A combinatorial strategy for treating KRAS-mutant lung cancer
- (2016) Eusebio Manchado et al. NATURE
- Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
- (2016) P. Lito et al. SCIENCE
- Molecular Heterogeneity of Ewing Sarcoma as Detected by Ion Torrent Sequencing
- (2016) Nana Zhang et al. PLoS One
- Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer
- (2015) P A Jänne et al. BRITISH JOURNAL OF CANCER
- Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer
- (2015) P. Pettazzoni et al. CANCER RESEARCH
- Identification of a Novel Pathogenic Germline KDR Variant in Melanoma
- (2015) I. P. Silva et al. CLINICAL CANCER RESEARCH
- KRAS-G12C Mutation is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma
- (2015) Ernest Nadal et al. Journal of Thoracic Oncology
- Whole genomes redefine the mutational landscape of pancreatic cancer
- (2015) Nicola Waddell et al. NATURE
- Molecular landscape of pancreatic cancer: implications for current clinical trials
- (2015) Gregory M. Heestand et al. Oncotarget
- Inhibition of the Growth of Patient-Derived Pancreatic Cancer Xenografts with the MEK Inhibitor Trametinib Is Augmented by Combined Treatment with the Epidermal Growth Factor Receptor/HER2 Inhibitor Lapatinib
- (2015) Dustin M. Walters et al. NEOPLASIA
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
- (2014) L. Rahib et al. CANCER RESEARCH
- A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors
- (2014) P. L. Bedard et al. CLINICAL CANCER RESEARCH
- A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
- (2014) Jeffrey R. Infante et al. EUROPEAN JOURNAL OF CANCER
- COSMIC: exploring the world's knowledge of somatic mutations in human cancer
- (2014) Simon A. Forbes et al. NUCLEIC ACIDS RESEARCH
- Discovery of Novel AKT Inhibitors with Enhanced Anti-Tumor Effects in Combination with the MEK Inhibitor
- (2014) Melissa Dumble et al. PLoS One
- KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer
- (2013) D. P. Modest et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Subtype-Specific MEK-PI3 Kinase Feedback as a Therapeutic Target in Pancreatic Adenocarcinoma
- (2013) O. K. Mirzoeva et al. MOLECULAR CANCER THERAPEUTICS
- Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
- (2012) Nathan T. Ihle et al. JNCI-Journal of the National Cancer Institute
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma
- (2012) Eric A. Collisson et al. Cancer Discovery
- Novel Functional Germline Variants in the VEGF Receptor 2 Gene and Their Effect on Gene Expression and Microvessel Density in Lung Cancer
- (2011) Dylan M. Glubb et al. CLINICAL CANCER RESEARCH
- A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy
- (2011) György Bodoky et al. INVESTIGATIONAL NEW DRUGS
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- Ligand-dependent Notch Signaling Is Involved in Tumor Initiation and Tumor Maintenance in Pancreatic Cancer
- (2009) M. E. Mullendore et al. CLINICAL CANCER RESEARCH
- Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
- (2008) S. Jones et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started